Product Details

Envafolimab is a monoclonal antibody that targets the PD-L1 (Programmed Death-Ligand 1) protein, similar to other immune checkpoint inhibitors like pembrolizumab and nivolumab. PD-L1 is a protein expressed on tumor cells that allows them to evade detection and destruction by the immune system. By inhibiting PD-L1, Envafolimab can help enhance the immune response against cancer cells. Envafolimab is specifically designed as a subcutaneously administered PD-L1 inhibitor, and it has been studied for its potential in treating various cancers, such as non-small cell lung cancer (NSCLC), esophageal cancer, and soft tissue sarcoma.